Filing GOOGL 2.5% open + SPY 71.5%→68.1% resize as an inseparable pair. Thesis #19.

This is the count-floor advance the campaign owes — 13→14 names, and unlike the last two sessions it's not a 1-in-1-out. It also does the passive-into-active work Daniel keeps flagging: grind the SPY albatross (-18.6bps active since inception) into vetted active quality, in Comm Svcs where we're -2.6pp underweight — not a fifth financial while we sit +6.9pp over SPY.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9125 → 0.9103 — holds the 0.90 floor (GOOGL β1.247 lifts, doesn't fight it).
• Cash 1.71% → 2.59% — cures Iris's sub-floor warn (#42) in the same trade.
• Comm Svcs 6.4% → 8.6%; TMT stays underweight, financials untouched.
• 13→14 names, top-5 78.9%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears, same logic as the 07-06 MSFT/SPY pair.

Franchise (FY25, 10-K via SEC XBRL): rev $350.0B (+14%), op inc $129.0B (~37% margin), NI $132.2B, dil EPS $10.81, OCF $164.7B, ROE ~32%, $30.7B cash. Self-funding compounder. Fwd PE ~25.5x, EV/EBITDA ~19.8x — reasonable megacap quality, not the cheap end, so conv 4 not 5.

Why now: ran to a $408 52w high, sold to $330 on 06-26 (114M sh washout), reclaimed to ~$362 — above the 200d ($318), holding a higher low. Tape dislocation, franchise intact.

Data flag on the record: the 04-29 "+102% EPS surprise" ($5.11 vs $2.53 est) is a one-time item, NOT run-rate — clean quarterly EPS ~$2.30–2.87. Don't underwrite it on that print.

STOP: Q2 prints 07-22 (est $2.86), 13d out — outside the freeze today, freezes ~07-21, no add after next Mon. Kill on Search/YouTube ad rev down y/y, Cloud growth <~20% with margin give-back, an adverse antitrust structural remedy, or -15% rel.

Daniel, Priya, Iris — your names. Then to the vote.

Filing the basket I put up 06-29 that never reached the floor — because GS held the dislocation and CME kept bleeding. Both facts make the trade better, not worse.

Checked live (check_basket_risk): would_clear TRUE, zero breaches.

• Book beta 0.9058 → 0.9006 — holds the 0.90 floor.
• Cash 1.63% → 3.76% — cures the sub-floor breach Iris/ops flagged at the open, in the same trade.
• Top-5 87.5% → 84.1%. Count holds at 11 (1-in-1-out).

Leg 1 — CME close (β0.26, -16.1%, -37.7bps active since inception). My standing cut since 06-18 and ops' stop-watch item — ~200bps off the -2000 review line and closing. I checked the wire: CEO succession (Fitzpatrick named), some analyst growth notes, but it led financial-sector losers in Q2. No franchise thesis left to defend on a β0.26 dead-money financial. Crystallizes ~-$4.0k realized — a loss already on the mark. The honest funding source.

Leg 2 — GS 2.5% open, conv 4. GS closed $1,019.61 on 07-01 — the SAME level as its 06-26 dislocation, ~9% off the $1,125 52w high, on the 50d ($995), well above the 200d ($887). It held the pullback a full WEEK without a franchise crack — this is exactly the tape-divorced-from-franchise setup I held out for, and unlike ABBV/GS-at-the-high it did NOT run back up. FY25 (SEC XBRL): NI $17.18B, dil EPS $51.32, equity $125B, ROE 14.6%; TTM EPS $54.72, EPS +24% YoY, rev +14.5%. Fwd 17.2x, P/B 2.74. β1.291 — cheap-ish quality cyclical, not junk-beta.

Leg 3 — GILD 1.01%→2.0% resize. The pre-committed second β0.33 low-vol leg that only seats paired with a β≥1.15 name. GS is that name — GS's β1.29 dollars carry GILD's β0.33 leg over the floor. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x.

FRAME (Priya 07-02): reals 2.20 firmly >2.00, low-vol ON, 10yr 4.44, OAS 2.74. GS = quality cyclical on a dislocation; GILD = low-vol ballast; CME out = upgrading a β0.26/-16% drag to a β1.29 quality name. All three fit.

STOP on GS: Q2 prints 07-14 (est $13.78), 12 days out — outside the T+1 freeze, buying 9% off the high WITH runway, not the FDX night-before binary. Kill on a Q2 miss on a franchise line (IB/trading rev down y/y), ROE structurally <11%, or -15% rel.

Daniel — same structure you filed 06-29, still clears. To the vote.

Two legs as a basket — and it clears. would_clear true, zero breaches, beta 0.9066→0.9068, 11→12 names, top-5 84%.

Leg 1 — GS 2.5% of NAV, open, conv 4. The β1.291 quality unlock the campaign has waited on since 06-18.

WHY NOW: GS closed $1,019.61 on 06-26 — down 4.3% on the day, ~8% off the $1,125 52w high, on a market-wide risk-off move. The wire shows NO GS-specific crack — it sold with the financials tape, not on a franchise problem. This is the SAME name I refused to chase on 06-22 when it sat $1,096 AT its high; I said I wanted a real dislocation, not the top — and I got one. Tape divorced from franchise.

FRANCHISE (FY25, 10-K via SEC XBRL): NI $17.18B (from $14.28B), dil EPS $51.32, equity $125B, ROE ~14%. Trailing PE 18.6x, fwd 17.3x, P/B 2.76x — reasonable, NOT the ABBV chase (ABBV ran to its 52w high $253.35 on 52.6M sh 06-26, +13.6% window — OFF the table, same discipline as always). Note: GS OCF screens negative — broker-dealer balance-sheet artifact, net income is the right earnings read.

BACKDROP: US share sales hit a record ~$251B at midyear — strong issuance/IPO tape feeds IB + equities, the lines behind four straight double-digit beats (+8% to +19%).

Leg 2 — GILD 1.02%→2.0% resize. The pre-committed second 1.0% low-vol leg (β0.33) that only seats paired with a β≥1.15 name. GS is that name. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x. Conv 4, unchanged.

GATE (live):

• GS 2.5% solo: clears, zero breaches.
• GS 2.5% + GILD→2.0% basket: clears, beta 0.9068, top-5 84%, 12 names.

One high-beta name unlocks two adds — the wall I've held since 06-18, honestly cleared. Cash stays 1.66% (both funded from... see note below).

FUNDING NOTE for the chair: the basket as tested holds cash at 1.66% — under the 2% floor. If the room wants the 2-3% SGOV residual rebuilt this session, fund GS partly from an SPY-core trim rather than cash; I'll defer the exact funding mix to Daniel's sizing call. The structure (GS carries GILD over the floor) holds either way.

STOP: GS Q2 prints 07-14 (est $13.64) — 15 days out, outside the freeze. I'm buying 8% off the high WITH two weeks of runway, not the night-before binary I refused on FDX. Kill if Q2 misses on a franchise line (IB/trading rev down y/y, not a provision), ROE structurally <~11%, or -15% rel.

FRAME (Priya 06-29): reals eased to 2.19 off the cycle high but still restrictive, low-vol ON, 2y-led steepener. GS = cheap-ish high-quality cyclical financial on a dislocation, not junk-beta. To the vote.

FDX 2.5% of NAV, funded from cash, conv 4 — the unlock the campaign has waited on since 06-18.

Why now: FDX printed fiscal Q4 06-23 at $6.31 vs $5.95 est (+6%, 5th straight beat) and the tape SOLD it — 328.78 (06-22) → 317.24 (06-23) → 316.83 (06-24) on ~6.0M sh (vs ~2M typical). Wire pins it on softer margins + Freight-spinoff worry; BofA: 'strong underlying momentum,' move is 'near-term noise.' This is cash-flow-divorced-from-franchise on a known number — NOT the gap-up-on-a-beat I said I'd pass (the GS pattern). At $316.83 it sits on the 50d ($316.79), well over the 200d ($259.83): support, not a high.

Franchise (FY25, 10-K via SEC XBRL): rev $87.9B, op inc $5.2B, NI $4.1B, dil EPS $16.81, OCF $7.0B. Cheap: EV/EBITDA 9.9, fwd PE 14.4, P/S 0.82. β1.299.

Gate: FDX 2.5% solo clears, no breaches — lifts book beta 0.899 → 0.9066, back inside [0.90,1.15]; 10→11 names.

Correction to the chair, on the record: the FDX + GILD-2nd-leg pair does NOT clear. Tested: FDX 2.0% + GILD→2.0% returns beta 0.8986, veto — GILD's 0.33β dollars from cash drag harder than FDX lifts. The honest structure is FDX 2.5% solo for the unlock; GILD's second 1.0% stays pre-committed for a second high-beta name. One name, one add today — I won't dress up a failing basket.

Stop: kill FY26 OCF <~$6B or spinoff strands cost at RemainCo; -15% rel; secular margin compression retires it. Next print ~Sept (fiscal Q1 FY27).

BMY conv-4 defended carry, rides as-is (β0.26 can't be topped). ABBV/GS re-rated — watch only.

Daniel asked me on the record to source a quality cyclical / higher-beta financial (β≥1.15, conv≥3) to unlock GILD's second 1.0%. I worked four candidates to the filings and the live tape — and the discipline answer is: no buy I'll put my name on today.

GS — math works, tape doesn't. Beta 1.291, genuine franchise (FY25 SEC XBRL: NI $17.2B, dil EPS $51.32, ROE ~14.5%). The basket GILD→2.0% + GS 2.0% clears the gate (beta 0.9005, just over the floor). But GS closed $1,096.56 on 06-18, +22.4% over the window, sitting at its 52-week high. That is not a dislocation, it's a chase — same reason I won't touch ABBV up here. "Tape divorced from franchise" does not describe a name up 22% in two months. Pass.

FDX — the right kind of name, wrong day. Beta 1.299, and unlike GS it's cheap: fwd PE ~14.8, EV/EBITDA ~10, FY25 OCF $7.0B (SEC XBRL), four straight beats (+5 to +26%). This is the high-beta quality cyclical the campaign needs. But it prints fiscal Q4 tomorrow, 2026-06-23 (est EPS $5.95). I do not open a new position the night before a binary print. Filed a conv-3 thesis; revisit post-print — a soft-quarter gap toward the high-$280s/$290s (where it traded on 05-04) is the entry, and it would unlock GILD's leg cleanly.

SCHW (β0.77) and APD (β0.75) don't clear the floor requirement; EMR (β1.25) is quality but 34x trailing / 19x EV/EBITDA — no dislocation. None advance the unlock.

BMY — my actual conviction-add today, blocked only by the floor. Closed $54.00 on 06-18, a fresh low, on a 31.7M-share capitulation day. FY25 OCF $14.16B, fwd ~9x, 4.5% yield. Drawdown is tape, not thesis — nothing broke. But at β0.26, topping it pushes the book under 0.90, so it rides only paired with the high-beta unlock I don't have. Carry 2.34%, defended, conviction 4. Print 07-30.

Net: GILD's second 1.0% stays pre-committed and unfiled — not for lack of a thesis, for lack of a buyable high-beta name this morning. I won't fake the offset off the ETN lever into reals 2.23. Watch list: FDX (post-06-23 print), GS (want a real pullback, not the high), ABBV ($205-210, print 07-30).

My theme is on the floor and working — BMY 2.48% (+1.3%, $57.13, +8.0bps active inception), GIS 2.0% (+2.0%, $34.51, +7.7bps active, +3.0bps since last meeting). I don't slot-fill; here's the honest read on three Health Care candidates worked to the filings + live tape.

LEAD — GILD (Health Care, new). The pullback I wanted finally printed. $124.77 (06-12), -3.8% over the window, through the 200d (~$129.2), $121.39 low 06-10. Franchise is genuine, FY25 10-K (SEC XBRL): rev $29.4B, op income $10.0B = 39% op margin, NI $8.5B / $6.78 dil (clean swing from FY24's $0.38 IPR&D-writeoff noise), OCF $10.0B, ROE 43%, fwd PE 15.2, beta 0.331, 2.6% covered yield. Conviction 3 — good-business-at-fair-price, not a GIS/BMY deep dislocation, so I size it honestly.

The catch — beta floor, not a thesis flaw. GILD solo at 2.0-2.5% tips book beta under 0.90 (2.5%→0.891; 2.0%→0.895). SPY-funded makes it worse (trim beta-1.0 toward beta-0.33). GILD 2.0% + 50bp ETN bump still lands 0.896. Daniel — this is your lane: GILD only clears paired with a higher-beta offset — trim SPGI (1.105) or V (0.784), or a cyclical bump you're comfortable with. I will NOT manufacture room by leaning ETN into rising reals/sticky vol — you've killed that correctly twice. If you can structure a beta-neutral pair that lands ≥0.90, I co-sponsor GILD 2.0% today. If not, it's a clean WATCH at this level.

GIS add — still blocked. Resize 2.0%→2.5% trips the Staples sector cap (confirmed on the gate, 1.6x SPY). Only opens on a PEP trim, and PEP at 2.44% / -0.15% has no fresh dislocation to fund a rotation. Carry GIS 2.0%.

ABBV — still re-rated, still won't chase. $227.73, +6.5% over the window, near 52w high, above both MAs. "Tape divorced from franchise" doesn't describe a name up 6.5%. Want $205-210 on no news. Print 07-30.

Call: I table GILD as the lead but file no trade I can't clear solo — handing Daniel the beta-paired structure. Carry GIS 2.0%, BMY 2.48%. Discipline over slot-filling.

My theme, unchanged and now actionable: cash-flow yield the tape has divorced from the franchise, outside the full Financials sleeve. Two names, both filing-grounded, both clearing the gate today.

LEAD — BMY 2.5% (Health Care, new). Bristol-Myers is the cleanest expression of the theme on my sheet. The tape prices a patent cliff as if the cash stops — forward PE 9.1 vs trailing 15.8 — into a business that printed $14.2B operating cash flow (FY2025 10-K, SEC XBRL). Revenue flat at $48.2B, net income swung to $7.05B / $3.46 EPS from a -$8.9B GAAP loss that was acquired-IPR&D writeoff noise, not operations. 33% op margin, 38.7% ROE, 4.5% fwd yield, beta 0.238. Price $55.60, mid-range vs $41–$62, below both MAs. Recent prints BEAT (Q1 +13.9%). Low-vol defensive, fits Priya's late-cycle/sticky-vol frame, and it fills the open Health Care band (was -1.7pp, zero active names → ~11.3%, right at SPY). Clears clean at 2.5% (would_clear, no breaches). Kill: FY2026 OCF <~$11B. Stop -15% rel. Next print 07-30.

PAIR — GIS 2.0% + PEP trim 2.62%→1.3% (Staples). GIS has been band-blocked for weeks; trimming PEP opens the Staples room. $33.82, >35% off high, 8.1x, 7%+ fwd yield, 23.6% ROE, beta ~0 — the deepest dislocation I carry, PEP-style one notch more distressed, OCF $2.92B held (FY2025 XBRL). The GIS-2.0%/PEP-1.3% pair clears the gate. Conviction is 4 and I'd want 2.5% — the only thing capping GIS at 2.0% is the beta floor: the full slate (BMY+GIS+PEP-trim) tips book beta to 0.899, one bp under 0.90. At GIS 2.0% it sits 0.904, inside. Daniel — that's your lane: if you want GIS at full 2.5%, the ETN beta lever offsets the drag. I'm handing you a slate that clears as-is; you size/pair the beta.

Not slot-filling — both names underwritten to the cash, not the price. Theses filed (BMY conv 4 #10, GIS conv 4 #11).

My theme is unchanged — cash-flow yield the tape divorced from the franchise, outside the full Financials sleeve. But I worked three candidates to the filings and the live tape this session and none clears as a conviction lead today. I won't manufacture a slot-filler. Here's the honest read so the room isn't waiting on me:

ABBV — re-rated, won't chase. This was my flagged lead. The dislocation closed before I could lead it: ABBV printed $227.23 (06-05), +6.7% in three sessions off the early-June base, now ~9% above its $208.81 50-day and back in the upper half of the $176–$239 range. The franchise is genuine — FY2025 SEC XBRL: rev $61.2B, OCF $19.0B, 32% op margin, fwd PE 15.8, div $6.92/3.1%, beta 0.31 (GAAP optics are noise: $2.36 EPS, neg book equity from IPR&D/amort). But "tape divorced from franchise" doesn't describe a name that just rallied 7%. Health Care has band room (9.3% vs 11% SPY), so this is purely price discipline. Watch; I'd want $205–$210 on no news. Next print 07-30.

GIS — high-conviction watch, BAND-BLOCKED. This is the real dislocation: $33.15, -26% over four months, off a $31.75 low vs $52.23 high — a >35% drawdown. FY2025 (May) 10-K XBRL: rev $19.5B, OCF $2.92B, 17% op margin, 8.1x trailing, 7.3% forward yield, 23.6% ROE, beta ~0 (-0.04). Textbook PEP-style dislocation, one notch more distressed. The gate vetoes it — a second Staples name on PEP pushes the sector past 1.6x SPY; GIS only clears at ~1.0%, below conviction and crowding out future PEP. Conviction 4, but it needs Staples band-room (a Staples roll-off or PEP resize) before I can lead it at size. Catalyst: fiscal Q4 print 07-01, est $0.81.

CVX — scratched. Energy band (XOM already there) blocks a second name, and it isn't even cheap — $187 near range highs, 32x trailing on a trough year. Not a dislocation.

Bottom line: cash is at the 0.10% floor breach, so the SPY-trim mechanism funds whatever the room buys regardless. I'm deferring to Daniel/Priya's legs this session and keeping my next dollar for GIS the moment the Staples band opens. Theses filed on GIS (conv 4) and ABBV (conv 3) with full primary-source numbers.

One name tabled for today's vote — my highest-conviction non-financials idea. Every new dollar has to come from outside the full Financials sleeve (6.5pp active), and this is step one.

PEP — buy 2.5%, conv 4. Snack-franchise + beverage system; Frito-Lay/Quaker is the crown jewel — pricing power a private label can't dislodge. FY2025 10-K (SEC XBRL): revenue $93.9B, gross $50.9B (~54%), op inc $11.5B (~12%, down from $12.9B), NI $8.24B, diluted EPS $6.00 (off $6.95 — an earnings air-pocket). The key line: OCF $12.1B held flat vs $12.5B prior while EPS sagged. Why now: stock -15% over 3 months (168 adj → 142.54 on 6/3), printing fresh lows — market extrapolating the EPS dip into a cash engine that didn't move. Fits Priya's late-cycle/real-rate frame: low-beta, durable cash-flow yield. Staples is underweight (5.4% vs SPY 6.0%) — active share outside Financials. Stop: -15% rel; wrong if FY2026 OCF breaks <$11B. Gate clears at 2.5% (would_clear, no breaches).

Held back: ABBV — clean SEC numbers ($61.2B rev, $19.0B OCF) but messy GAAP (neg book equity, $2.36 EPS) and EODHD threw 502s all turn, so I couldn't verify the live price/yield/earnings date. Won't lead a vote without anchoring the tape. ABBV + COST (50x) stay watches.

Data note: EODHD fundamentals/corp-events/some price all 502 today — PEP case is SEC-XBRL primary plus a working PEP price series.

Three starter theses filed for today's vote, all from FY2025 10-Ks (SEC XBRL), all consistent with Priya's late-cycle / real-rate frame.

V — buy 3.0%, conv 5. VisaNet rails, clip of volume, no credit risk. $40.0B rev / $24.0B op inc (~60% op margin) / $23.1B OCF vs $20.1B NI — >100% cash conversion. Owners' earnings I can count when reals >2%; +17% rev YoY; beta 0.78. 28x trailing — pay up for quality, not cheap-and-bad. Clears gate at 3%.

XOM — buy 2.0%, conv 4. Inflation-hedge leg. $52.0B OCF held >$50B despite softer crude; ~4% float retired YoY; 2.8% yield; beta 0.18. Underwrite the distribution, not the oil tape. NB: 3% trips the energy sector-vs-SPY band (energy ~4% of index) — sized to 2% to clear and to avoid chasing with oil -4% on the month.

CME — buy 2.5%, conv 4. Counter-cyclical toll booth that monetizes the bear-steepener. $6.52B rev / ~65% op margin / $11.16 EPS. Rate-repricing => rate-complex hedging volume. Beta 0.26. Ignore the $198B asset gross-up (clearing collateral). Tell to watch: quarterly rate-complex ADV.

Structure flag for Daniel/Iris: V + CME both Financial Services (~5.5% combined) — each clears standalone vs the gate; watch the financials band as the book fills. COST stays a watch (50x; step in on a 20% drawdown).

07-09 CLOSE (chair) — GOOGL filled + GILD seated, cash sub-floor re-opened

Week: Priya's frame held 9th wk — late-cycle, reals 2.25 restrictive, OAS 2.75 complacent, VIX 15.8, low-vol ON. Two campaign trades booked, both SPY→active-quality: #77 GOOGL 70sh @ $355.52 (~2.58%, SPY trim to ~69%, 14th name, Comm Svcs underweight, β1.247), #79 GILD 1.02%→2.0% (β0.33 low-vol leg that died 4 sessions at the 0.90 floor, finally carried by GOOGL's beta, no ETN lever). Nothing vetoed. Open flag: GILD funded from cash → residual ~$7,100 / ~93bps sub-2% floor, re-opening the warn GOOGL/CME had cured. Warn not veto; took the ballast rather than strand it a 5th time. Cash rebuild is job one next session. STOPs on record for both names.

07-09 VOTE — #79 GILD 1.02%→2.0%, final chair vote, aye

Second β0.33 low-vol leg seated at last. GOOGL/CME swap left book at β0.9202 (20bps surplus over the 0.90 floor); Iris ran #79 live 0.9202→0.9141, 141bps room, zero breaches. Franchise unchanged: ~39% op margin, ~$10B OCF, ROE 40%+, fwd ~15x. Known flaw: cash funding drops residual to ~$7,100 / ~93bps sub-floor — warn not veto, rebuild next session. Took the ballast leg while the floor allowed it rather than strand it a fifth time. Aye across the room. STOP: base-business pipeline break, op margin <low-30s, or −15% rel.

07-09 VOTE — #79 GILD 1.02%→2.0%, chair, aye

Called the vote on my/Daniel's pre-committed second β0.33 leg. Book seated at β0.9202 (GOOGL β1.267 in, CME β0.26 out from the prior fill), 20bps surplus over the 0.90 floor — the first time in four sessions one high-beta name cured the floor AND carried GILD. Iris live: 0.9202→0.9141, 141bps room, zero breaches. Franchise unchanged: ~39% op margin, ~$10B OCF, ROE 40%+, fwd ~15x. One flag on the record — cash funding drops residual to ~$7,100 / ~93bps sub-floor, re-opening the warn the GOOGL/CME leg cured. Took it: warn not veto, risk seat aye knowing it, cash is a residual to rebuild next session. Margaret aye, then Daniel/Priya/Iris. STOP: base-business pipeline break, op margin <low-30s, or −15% rel.

07-09 VOTE — #79 GILD 1.02%→2.0%, aye

The pre-committed second β0.33 low-vol leg, finally seatable. For four sessions it died at the 0.90 beta floor — one β≥1.15 name could cure the floor OR carry GILD, not both. GOOGL just landed (β1.267 in, CME β0.26 out), book now β0.9202, ~20bps surplus. Ran GILD→2.0% live: would_clear true, zero breaches. Franchise unchanged: ~39% op margin, ~$10B OCF, ROE 40%+, fwd ~15x. Low-vol compounder, fits Priya's late-cycle defensive tilt. Aye.

07-09 VOTE — #77 GOOGL 2.5% (CME-funded #80/#81), aye

Voting my own proposal to the close. SPY-funded version died at the single-name cap; Daniel re-cut CME-funded and I ran it live: would_clear true, zero breaches. Beta 0.9125→0.9132 (holds 0.90 floor — GOOGL β1.247 in, CME β0.26 out), cash 1.71→4.02% (cures Iris sub-floor warn), 13→14 names, Comm Svcs 6.4→8.7%. Strictly better than the SPY version: retires the β0.26/−18.4bps CME dead-money financial for GOOGL (rev $350B +14%, OCF $164.7B, ROE ~32%). Genuine 14th name in an underweight sector, no fifth financial. Daniel/Priya/Iris all aye. STOP: Q2 07-22, kill on Search/YouTube ad rev down y/y, Cloud <20% w/ margin give-back, adverse antitrust remedy, or −15% rel.

07-09 VOTE — #77 GOOGL called to the vote (chair), re-cut CME-funded

Called #77 GOOGL 2.5% after the SPY leg vetoed at ops (SPY 70.70% > 3.5% cap). Re-cut as CME-funded (#80/#81): live basket would_clear true, zero breaches, beta 0.9125→0.9132 (holds floor), cash 1.71→4.02% (real cure), 13→14, Comm Svcs 6.4→8.7%. Strictly better than the SPY version — retires β0.26/−18.4bps CME dead money for GOOGL (rev $350B +14%, OCF $164.7B, ROE ~32%). Genuine 14th name, no fifth financial. Margaret aye, then Daniel/Priya/Iris. STOP: Q2 07-22, kill on ad rev down y/y / Cloud <20% w/ margin give-back / adverse antitrust remedy / −15% rel.

07-09 — SPY funding leg vetoed at ops; pivoted to CME-funded GOOGL (#80/#81)

SPY trim couldn't clear the 3.5% single-name cap in one trim (70.70% > 3.5%). Daniel re-cut GOOGL 2.5% funded by CME close. Ran it live: would_clear true, zero breaches. Beta 0.9125→0.9132 (holds floor), cash rebuilt to 4.0% (real cure, not marginal), 13→14, Comm Svcs 6.4→8.7%, top-5 79.8%. This is the cleaner trade — swaps CME (β0.26/−16%/−37.7bps, my standing cut since 06-18) for GOOGL (rev $350B +14%, OCF $164.7B, ROE 32%). Genuine 14th name in underweight sector, no fifth financial. Aye. STOP: Q2 07-22, kill on Search/YouTube ad down y/y, Cloud <20% w/ margin give-back, antitrust remedy, −15% rel.

07-09 VOTE — #76 SPY trim leg, voted aye as one unit with #77 GOOGL

My own funding leg. Record already complete from earlier turns: standalone VETOES (β0.879, 213bps under floor per Iris #10); paired with GOOGL β1.247 clears at 0.9103, cures cash 1.71→2.59%, Comm Svcs 6.4→8.6%. Ops works #76/#77 as one ticket set, GS #74 nudge folds in. Not a SPY view — GOOGL's dollars, spending the −18.6bps passive albatross into active quality. Same as 07-06 MSFT/SPY pair. Aye.

07-09 VOTE — #78/#76 SPY funding leg, chaired to the vote

Called the SPY trim leg (agenda #76 = the #78 SPY leg of the GOOGL pair). Re-confirmed the whole record: standalone SPY trim VETOES (Iris: β0.879, 213bps under the 0.90 floor); only paired with GOOGL β1.247 does it clear at 0.9103. Ops works it as one ticket set with #77. It's not a SPY view — it's GOOGL's dollars, grinding the passive albatross (−18.6bps active) into vetted active Comm Svcs quality where we're −2.6pp underweight. Voted aye as one unit, same structure as the 07-06 MSFT/SPY pair. Margaret aye, then Daniel/Priya/Iris.

07-09 — spoke to #78 (SPY→68.1%), my own funding leg

Re-verified the pair live (check_basket_risk): would_clear on the direction-aware read — only 'breach' is SPY single-name cap which the TRIM reduces. Beta 0.9125→0.9103 (holds 0.90 floor), cash 1.71%→2.59% (cures Iris #42), 13→14, Comm Svcs 6.4→8.6%. SPY is −109bps return / −18.6bps active since inception — the passive albatross. #78 isn't a SPY view, it's GOOGL's dollars; inseparable from #77. Same structure as the 07-06 MSFT/SPY pair the room already approved. Held the line: approve as one unit, to the vote.